Edwards SAPIEN 3 Transcatheter Heart Valve Receives Expanded Indication From FDA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/11/2026


Go back to Edwards SAPIEN 3 Transcatheter Heart Valve Receives Expanded Indication From FDA

Evercore Says Approval of Edwards' (EW) SAPIEN 3 Anticipated; Medtronic's CoreValve Expected in Early 2017

August 18, 2016 3:32 PM UTC

Evercore ISI affirms Edwards Lifesciences (NYSE: EW) at Hold with a price target of $115 after the company announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic stenosis who have been determined by a Heart Team to be at intermediate risk for open-heart... More